GeneDx Holdings Corp. (WGS) - Net Assets
Based on the latest financial reports, GeneDx Holdings Corp. (WGS) has net assets worth $254.12 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($506.30 Million) and total liabilities ($252.18 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible equity quality of GeneDx Holdings Corp. to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $254.12 Million |
| % of Total Assets | 50.19% |
| Annual Growth Rate | 134.08% |
| 5-Year Change | -20.59% |
| 10-Year Change | N/A |
| Growth Volatility | 3499.07 |
GeneDx Holdings Corp. - Net Assets Trend (2020–2025)
This chart illustrates how GeneDx Holdings Corp.'s net assets have evolved over time, based on quarterly financial data. See WGS days of operational coverage to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for GeneDx Holdings Corp. (2020–2025)
The table below shows the annual net assets of GeneDx Holdings Corp. from 2020 to 2025. For live valuation and market cap data, see GeneDx Holdings Corp. market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $308.18 Million | +25.66% |
| 2024-12-31 | $245.25 Million | +7.56% |
| 2023-12-31 | $228.02 Million | -10.13% |
| 2022-12-31 | $253.71 Million | -34.63% |
| 2021-12-31 | $388.10 Million | +8744.64% |
| 2020-12-31 | $4.39 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to GeneDx Holdings Corp.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 104344400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $3.00K | 0.00% |
| Other Comprehensive Income | $936.00K | 0.30% |
| Other Components | $1.68 Billion | 545.37% |
| Total Equity | $308.18 Million | 100.00% |
GeneDx Holdings Corp. Competitors by Market Cap
The table below lists competitors of GeneDx Holdings Corp. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sixt SE
XETRA:SIX3
|
$1.18 Billion |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
$1.18 Billion |
|
United States Steel Corp
BA:X
|
$1.18 Billion |
|
Shanghai Jinqiao Export Processing Zone Development Co Ltd A
SHG:600639
|
$1.18 Billion |
|
Beijing Sanju Environmental
SHE:300072
|
$1.18 Billion |
|
Ramsay Generale De Sante
PA:GDS
|
$1.18 Billion |
|
Ami Organics Limited
NSE:AMIORG
|
$1.18 Billion |
|
Instalco Intressenter AB
ST:INSTAL
|
$1.18 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in GeneDx Holdings Corp.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 245,247,000 to 308,182,000, a change of 62,935,000 (25.7%).
- Net loss of 21,021,000 reduced equity.
- New share issuances of 46,704,000 increased equity.
- Other comprehensive income increased equity by 106,000.
- Other factors increased equity by 37,146,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-21.02 Million | -6.82% |
| Share Issuances | $46.70 Million | +15.15% |
| Other Comprehensive Income | $106.00K | +0.03% |
| Other Changes | $37.15 Million | +12.05% |
| Total Change | $- | 25.66% |
Book Value vs Market Value Analysis
This analysis compares GeneDx Holdings Corp.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.15x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 75.67x to 5.15x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $0.78 | $59.01 | x |
| 2021-12-31 | $118.50 | $59.01 | x |
| 2022-12-31 | $24.78 | $59.01 | x |
| 2023-12-31 | $9.38 | $59.01 | x |
| 2024-12-31 | $9.12 | $59.01 | x |
| 2025-12-31 | $11.46 | $59.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently GeneDx Holdings Corp. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -6.82%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -4.92%
- • Asset Turnover: 0.75x
- • Equity Multiplier: 1.85x
- Recent ROE (-6.82%) is above the historical average (-980.81%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -5500.00% | -134.58% | 0.71x | 57.35x | $-241.78 Million |
| 2021 | -63.23% | -115.64% | 0.38x | 1.43x | $-284.20 Million |
| 2022 | -216.39% | -233.91% | 0.43x | 2.15x | $-574.35 Million |
| 2023 | -77.09% | -86.77% | 0.48x | 1.84x | $-198.57 Million |
| 2024 | -21.32% | -17.12% | 0.73x | 1.71x | $-76.81 Million |
| 2025 | -6.82% | -4.92% | 0.75x | 1.85x | $-51.84 Million |
Industry Comparison
This section compares GeneDx Holdings Corp.'s net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $655,728,646
- Average return on equity (ROE) among peers: -117.68%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| GeneDx Holdings Corp. (WGS) | $254.12 Million | -5500.00% | 0.99x | $1.18 Billion |
| Agilent Technologies Inc (A) | $4.63 Billion | -22.30% | 0.77x | $35.96 Billion |
| Advanced Biomed Inc. Common Stock (ADVB) | $976.24K | -188.19% | 0.03x | $6.13 Million |
| Applied DNA Sciences Inc (APDN) | $8.97 Million | -77.97% | 0.43x | $3.99 Million |
| Biodesix Inc (BDSX) | $20.88 Million | -205.65% | 3.66x | $79.44 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.07 Million | 0.00% | 0.00x | $3.77 Million |
| Biocept Inc. (BIOCQ) | $8.86 Million | -362.16% | 2.48x | $525.00 |
| BillionToOne, Inc. Class A Common Stock (BLLN) | $480.11 Million | 1.55% | 0.32x | $4.36 Billion |
| Burning Rock Biotech Ltd (BNR) | $1.16 Billion | -83.85% | 0.37x | $63.90 Million |
| CareDx Inc (CDNA) | $261.33 Million | -72.81% | 0.79x | $1.13 Billion |
| Check Cap Ltd (CHEK) | $5.91 Million | -165.47% | 0.34x | $9.42 Million |
About GeneDx Holdings Corp.
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and can… Read more